Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.

Axel Grothey,Alfredo Falcone,Yves Humblet,Olivier Bouché,Laurent Mineur,Antoine Adenis,Josep Tabernero,Takayuki Yoshino,Heinz-Josef Lenz,Richard M. Goldberg,Lei Xu,Andrea Wagner,Eric Van Cutsem

Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.

2015

Axel Grothey
Alfredo Falcone
Yves Humblet
Olivier Bouché
Laurent Mineur
Antoine Adenis
Josep Tabernero
Takayuki Yoshino
Heinz-Josef Lenz
Richard M. Goldberg
Lei Xu
Andrea Wagner
Eric Van Cutsem

710 Background: In the CORRECT phase III trial (NCT01103323), the multikinase inhibitor REG significantly improved overall survival (OS) and PFS vs placebo in patients with mCRC who had disease pro...

Keywords:

Regorafenib
multikinase inhibitor
in patient
Medicine
Progression-free survival
Internal medicine
Placebo
Subgroup analysis
Disease
Colorectal cancer
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations